



KDCA

Korea Disease Control and Prevention Agency

Updates on COVID-19 in Republic of Korea

30 April 2021

COVID-19 vaccination status as of 0:00 today (cumulative since 26 February 2021)

	Total	City							
		Seoul	Busan	Daegu	Incheon	Gwangju	Daejeon	Ulsan	Sejong
New (1st dose)	241,967	33,484	17,482	10,926	12,994	6,276	7,278	3,714	867
New (1st dose)	30,010	3,921	1,738	1,467	1,546	1,074	418	1,300	206
Total (1st)	3,056,004	472,376	192,612	129,103	151,132	97,804	85,809	53,032	14,683
Total (2nd)	198,734	31,620	10,330	7,104	15,734	6,761	6,132	8,821	2,008
		Province							
		Gyeonggi	Gangwon	Chung-buk	Chung-nam	Jeon-buk	Jeon-nam	Gyeong-buk	Gyeong-nam
New (1st dose)	56,575	10,865	9,676	11,645	13,527	15,263	15,835	13,095	2,465
New (1st dose)	4,824	1,803	1,538	2,066	1,587	2,119	1,969	1,738	696
Total (1st)	660,097	114,603	116,946	152,555	165,156	182,443	201,163	228,966	37,524
Total (2nd)	30,023	12,214	11,247	11,165	11,035	10,454	6,130	12,548	5,408

※ Figures subject to correction recording update

Adverse events following COVID-19 vaccination reported as of 0:00 today (cumulative since 26 February 2021)

		Vaccinated (cumulative)	Total	%	General ¹⁾	Anaphylaxis suspected ²⁾	Severe suspected ³⁾	Deaths
Total	New	3,254,738	499	0.48%	491	5	3	-
	Total		15,499		15,203	167	56	73
AstraZeneca	New	1,640,619	349	0.82%	347	2	-	-
	Total		13,485		13,274	135	33	43
Pfizer	New	1,614,119	150	0.12%	144	3	3	-
	Total		2,014		1,929	32	23	30

¹⁾ Mild cases such as headache, fever, nausea, vomiting, etc.

²⁾ Anaphylactoid reaction and anaphylactic shock suspected cases reported by healthcare institutions; Anaphylactoid reaction refers to occurrence of symptoms such as shortness of breath, rashes, etc. within 2 hours of vaccination and differs from anaphylaxis

³⁾ Includes convulsion and other nervous system response and ICU admitted cases

※ Based on the patient's condition at the time of initial report (general, anaphylaxis suspected, severe suspected, death)

※ Cases reported as suspected cases of AEFI; causal association not yet determined; investigation for assessment of causal association to take place for deaths or anaphylaxis cases



KDCA

Korea Disease Control and Prevention Agency

Updates on COVID-19 in Republic of Korea

30 April 2021

Confirmed cases by gender and age group

		New cases (%)	Total cases (%)	Incidence rate* (per 100,000)
Total		661 (100)	122,007 (100)	235.32
Sex	Male	353 (53.40)	60,745 (49.79)	234.87
	Female	308 (46.60)	61,262 (50.21)	235.76
Age	80 or above	35 (5.30)	5,325 (4.36)	280.38
	70-79	40 (6.05)	8,822 (7.23)	244.57
	60-69	96 (14.52)	18,783 (15.40)	296.06
	50-59	103 (15.58)	22,568 (18.50)	260.39
	40-49	109 (16.49)	18,068 (14.81)	215.37
	30-39	100 (15.13)	16,432 (13.47)	233.24
	20-29	104 (15.73)	18,196 (14.91)	267.34
	10-19	44 (6.66)	8,530 (6.99)	172.66
0-9	30 (4.54)	5,283 (4.33)	127.34	

* Total (cumulative) number of cases reported since January 2020 by sex and age / Population by sex and age (based on resident registration data of the Ministry of the Interior as of January 2020)

※ Figures subject to correction based on findings from epidemiological investigations

Deaths and severe/critical patients by gender and age group

		New deaths (%)	Total deaths (%)	Case fatality rate (%)	Severe/critical (%)
Total		3 (100)	1,828 (100)	1.50	164 (100)
Sex	Male	2 (66.67)	908 (49.67)	1.49	104 (63.41)
	Female	1 (33.33)	920 (50.33)	1.50	60 (36.59)
Age	80 or above	1 (33.33)	1,005 (54.98)	18.87	39 (23.78)
	70-79	0 (0.00)	523 (28.61)	5.93	58 (35.37)
	60-69	2 (66.67)	214 (11.71)	1.14	40 (24.39)
	50-59	0 (0.00)	62 (3.39)	0.27	17 (10.37)
	40-49	0 (0.00)	14 (0.77)	0.08	7 (4.27)
	30-39	0 (0.00)	7 (0.38)	0.04	2 (1.22)
	20-29	0 (0.00)	3 (0.16)	0.02	1 (0.61)
	10-19	0 (0.00)	0 (0.00)	0.00	0 (0.00)
0-9	0 (0.00)	0 (0.00)	0.00	0 (0.00)	

* Case fatality rate (CFR) (%) = Number of deaths / Number of confirmed cases x 100

※ Figures subject to correction based on findings from epidemiological investigations

AGE DISTRIBUTION OF SEVERE/CRITICAL CASES

	4.17.	4.18.	4.19.	4.20.	4.21.	4.22.	4.23.	4.24.	4.25.	4.26.	4.27.	4.28.	4.29.	4.30.
Total	108	102	99	109	116	125	127	136	136	132	156	160	157	164

* Severe/Critical: COVID-19 patients in isolation being treated with high flow oxygen therapy, mechanical ventilator, ECMO (Extracorporeal Membrane Oxygenation), CRRT (Continuous Renal Replacement Therapy)